Pacific Biosciences of California (PACB) Competitors

Pacific Biosciences of California (NASDAQ:PACB) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Do analysts rate PACB or HBIO?

Pacific Biosciences of California presently has a consensus target price of $2.34, indicating a potential upside of 148.42%. Harvard Bioscience has a consensus target price of $3.00, indicating a potential upside of 808.54%. Given Harvard Bioscience's higher possible upside, analysts plainly believe Harvard Bioscience is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56
Harvard Bioscience	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do institutionals & insiders have more ownership in PACB or HBIO?

80.9% of Harvard Bioscience shares are held by institutional investors. 2.5% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 9.0% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is PACB or HBIO more profitable?

Harvard Bioscience has a net margin of -14.57% compared to Pacific Biosciences of California's net margin of -200.40%. Harvard Bioscience's return on equity of -4.64% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-200.40%	-42.89%	-14.77%
Harvard Bioscience	-14.57%	-4.64%	-2.40%

Does the media prefer PACB or HBIO?

In the previous week, Pacific Biosciences of California had 5 more articles in the media than Harvard Bioscience. MarketBeat recorded 5 mentions for Pacific Biosciences of California and 0 mentions for Harvard Bioscience. Pacific Biosciences of California's average media sentiment score of 0.09 beat Harvard Bioscience's score of 0.00 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Overall Sentiment
Pacific Biosciences of California	Neutral
Harvard Bioscience	Neutral

Which has higher earnings and valuation, PACB or HBIO?

Harvard Bioscience has lower revenue, but higher earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$152.36M	1.85	-$308.65M	-$2.79	-0.34
Harvard Bioscience	$91.40M	0.16	-$3.41M	-$1.32	-0.25

Does the MarketBeat Community prefer PACB or HBIO?

Pacific Biosciences of California received 84 more outperform votes than Harvard Bioscience when rated by MarketBeat users. However, 71.15% of users gave Harvard Bioscience an outperform vote while only 66.37% of users gave Pacific Biosciences of California an outperform vote.

Company	Underperform	Outperform
Pacific Biosciences of California	Outperform Votes 454 66.37%	Underperform Votes 230 33.63%
Harvard Bioscience	Outperform Votes 370 71.15%	Underperform Votes 150 28.85%

Which has more volatility & risk, PACB or HBIO?

Pacific Biosciences of California has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.

Summary

Pacific Biosciences of California and Harvard Bioscience tied by winning 9 of the 18 factors compared between the two stocks.